title: Non-melanoma skin cancer.
abstract: Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common. Surgery has traditionally been regarded as the 'gold-standard' treatment, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (radiotherapy, curettage and cautery, and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.
authors.affiliation: Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK.
authors.forename: Liezel L
authors.initials: LL
authors.lastname: Griffin
authors.affiliation: St John's Institute of Dermatology, St Thomas' Hospital, London, UK.
authors.forename: Faisal Rehman
authors.initials: FR
authors.lastname: Ali
authors.affiliation: Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK john.lear@cmft.nhs.uk.
authors.forename: John T
authors.initials: JT
authors.lastname: Lear
mesh_terms: D002280:Basal Cell Carcinoma; D002294:Carcinoma, Squamous Cell; D006801:Humans; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms
keywords: Non-melanoma skin cancer; basal cell carcinoma; dermatology; squamous cell carcinoma; surgery
references.citation: Br J Dermatol. 2002 Jan;146(1):18-25
references.pmid: 11841362
references.citation: BMJ. 2003 Oct 4;327(7418):794-8
references.pmid: 14525881
references.citation: N Engl J Med. 2005 Nov 24;353(21):2262-9
references.pmid: 16306523
references.citation: J Am Acad Dermatol. 2007 Jan;56(1):125-43
references.pmid: 17190630
references.citation: Adv Exp Med Biol. 2008;624:283-95
references.pmid: 18348464
references.citation: Br J Dermatol. 2008 Jul;159(1):35-48
references.pmid: 18593385
references.citation: Nature. 2010 Jan 14;463(7278):191-6
references.pmid: 20016485
references.citation: Lancet. 2010 Feb 20;375(9715):673-85
references.pmid: 20171403
references.citation: Br J Dermatol. 2012 May;166(5):1069-80
references.pmid: 22251204
references.citation: N Engl J Med. 2012 Jun 7;366(23):2225-6
references.pmid: 22670909
references.citation: J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1118-26
references.pmid: 2273112
references.citation: J Natl Cancer Inst. 2013 Mar 6;105(5):350-60
references.pmid: 23291375
references.citation: Br J Dermatol. 2013 Jul;169(1):53-7
references.pmid: 23488543
references.citation: J Clin Oncol. 2014 Mar 10;32(8):745-51
references.pmid: 24493717
references.citation: Br J Dermatol. 2014 Sep;171(3):443-5
references.pmid: 25234058
references.citation: Lancet Oncol. 2015 Jun;16(6):716-28
references.pmid: 25981810
references.citation: Lancet Oncol. 2015 Jun;16(6):729-36
references.pmid: 25981813
references.citation: J Dermatol Surg Oncol. 1989 Mar;15(3):315-28
references.pmid: 2646336
references.citation: J Dermatol Surg Oncol. 1989 Apr;15(4):424-31
references.pmid: 2925988